Evidence map›Paper›PMID 40556780›Full record

ArticleACS bio & med chem Au2025

Discovery of Iboga-Derived Ligands for the Sigma‑2 Receptor.

Alexander J Hughes, Julie A Talbert, Steven D Townsend

Abstract read
In one paragraph

Article in ACS bio & med chem Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander J HughesDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID https://orcid.org/0009-0009-7107-7439
Julie A TalbertDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
Steven D TownsendDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID https://orcid.org/0000-0001-5362-7235

Funding

Bioorganic Approaches Toward Novel Antimicrobial Agents and ChemotherapeuticsR35GM133602 · NIGMS · VANDERBILT UNIVERSITY · PI Steven D. Townsend · 2019 to 2026
$3.0M
NIGMS NIH HHS R35 GM133602
6 · The paper itself

Abstract

Substance use disorder (SUD) is a mental condition that affects a person's brain and behavior, leading to a lack of control with alcohol, drug, and medication use. The lack of efficacious and novel treatments for SUD is a growing concern. As such, we have synthesized a series of iboga alkaloid derivatives and evaluated their receptor binding profiles against a panel of CNS-based proteins, which were performed at the National Institute of Mental Health Psychoactive Drug Screening Program. These studies revealed two compounds that exhibit high affinity for the sigma-2 receptor and introduce the iboga alkaloid framework as a new scaffold for the development of sigma-2 ligands.

Indexed as

iboga alkaloidsibogaminemolecular modelingSigma-2 receptorsubstance use disorder

Identifiers

PMID40556780
PMCPMC12183592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.